Concepts (290)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sister Chromatid Exchange | 11 | 1990 | 60 | 0.780 |
Why?
|
| Phagocytes | 8 | 2007 | 297 | 0.770 |
Why?
|
| Medical Receptionists | 1 | 2017 | 2 | 0.620 |
Why?
|
| DNA Damage | 8 | 2007 | 2423 | 0.460 |
Why?
|
| Nitrosamines | 3 | 1999 | 87 | 0.430 |
Why?
|
| Anticarcinogenic Agents | 2 | 2007 | 253 | 0.420 |
Why?
|
| Medical Records | 1 | 2017 | 1413 | 0.400 |
Why?
|
| Antioxidants | 6 | 2007 | 1659 | 0.330 |
Why?
|
| Organoplatinum Compounds | 1 | 2010 | 408 | 0.320 |
Why?
|
| beta-Glucans | 1 | 2008 | 123 | 0.300 |
Why?
|
| Lovastatin | 1 | 2007 | 120 | 0.300 |
Why?
|
| Plants, Toxic | 2 | 1999 | 76 | 0.290 |
Why?
|
| Magnesium | 1 | 2010 | 813 | 0.280 |
Why?
|
| Oxygen | 10 | 1990 | 4169 | 0.280 |
Why?
|
| Free Radicals | 13 | 1999 | 236 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2008 | 11472 | 0.280 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2010 | 290 | 0.270 |
Why?
|
| Carcinogens | 2 | 1997 | 466 | 0.220 |
Why?
|
| Vitamin E | 5 | 1997 | 869 | 0.200 |
Why?
|
| Purpura | 1 | 2001 | 122 | 0.190 |
Why?
|
| Catechin | 1 | 1999 | 64 | 0.170 |
Why?
|
| Niacin | 2 | 1990 | 116 | 0.170 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 2 | 1990 | 226 | 0.170 |
Why?
|
| Diterpenes | 1 | 1999 | 173 | 0.160 |
Why?
|
| Leukotrienes | 2 | 1990 | 255 | 0.160 |
Why?
|
| Tea | 1 | 1999 | 275 | 0.150 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1998 | 110 | 0.150 |
Why?
|
| Arachidonic Acids | 2 | 1988 | 299 | 0.150 |
Why?
|
| Blood Component Transfusion | 1 | 1998 | 142 | 0.150 |
Why?
|
| Lymphocytes | 3 | 1990 | 2614 | 0.150 |
Why?
|
| beta Carotene | 2 | 1997 | 527 | 0.150 |
Why?
|
| Cricetinae | 11 | 1990 | 2471 | 0.140 |
Why?
|
| Neoplasms | 11 | 2008 | 21596 | 0.140 |
Why?
|
| Calcium | 1 | 2010 | 5753 | 0.140 |
Why?
|
| DNA | 4 | 1999 | 7289 | 0.140 |
Why?
|
| Reactive Oxygen Species | 3 | 2007 | 2077 | 0.130 |
Why?
|
| Colorectal Neoplasms | 5 | 2010 | 6754 | 0.130 |
Why?
|
| Pulmonary Edema | 1 | 1998 | 415 | 0.130 |
Why?
|
| Lipid Peroxides | 3 | 1990 | 73 | 0.130 |
Why?
|
| Superoxides | 3 | 1999 | 386 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1998 | 692 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2001 | 5171 | 0.120 |
Why?
|
| Neutropenia | 2 | 1992 | 891 | 0.110 |
Why?
|
| Etoposide | 5 | 2001 | 637 | 0.110 |
Why?
|
| Idarubicin | 2 | 1992 | 62 | 0.110 |
Why?
|
| Ascorbic Acid | 2 | 1987 | 647 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 3239 | 0.110 |
Why?
|
| Daunorubicin | 2 | 1992 | 149 | 0.110 |
Why?
|
| Ataxia Telangiectasia | 1 | 1993 | 107 | 0.110 |
Why?
|
| Mutagens | 1 | 1993 | 168 | 0.110 |
Why?
|
| Deferoxamine | 3 | 1990 | 151 | 0.100 |
Why?
|
| Doxorubicin | 1 | 1998 | 2215 | 0.100 |
Why?
|
| Stem Cells | 1 | 2005 | 3563 | 0.100 |
Why?
|
| Catalase | 5 | 1990 | 222 | 0.090 |
Why?
|
| Adenosine Deaminase Inhibitors | 1 | 1990 | 9 | 0.090 |
Why?
|
| Pentostatin | 1 | 1990 | 26 | 0.090 |
Why?
|
| Cytarabine | 2 | 1992 | 684 | 0.090 |
Why?
|
| Nucleoside Deaminases | 1 | 1990 | 58 | 0.090 |
Why?
|
| Tetradecanoylphorbol Acetate | 5 | 1999 | 821 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1990 | 245 | 0.090 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 1996 | 546 | 0.090 |
Why?
|
| Fluorouracil | 8 | 1996 | 1615 | 0.090 |
Why?
|
| Lung Neoplasms | 6 | 2001 | 13019 | 0.090 |
Why?
|
| Radiation, Nonionizing | 1 | 1989 | 6 | 0.090 |
Why?
|
| Fibroblasts | 5 | 1997 | 4143 | 0.080 |
Why?
|
| Cisplatin | 6 | 2001 | 1637 | 0.080 |
Why?
|
| Research Design | 1 | 2005 | 5979 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 1990 | 355 | 0.080 |
Why?
|
| Superoxide Dismutase | 5 | 1990 | 596 | 0.080 |
Why?
|
| Chloramines | 1 | 1987 | 14 | 0.080 |
Why?
|
| Glutathione | 2 | 1987 | 586 | 0.080 |
Why?
|
| DNA, Single-Stranded | 3 | 1997 | 353 | 0.080 |
Why?
|
| Autoimmune Diseases | 2 | 1992 | 2130 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 13655 | 0.070 |
Why?
|
| Lymphatic Diseases | 2 | 1986 | 324 | 0.070 |
Why?
|
| Thrombocytopenia | 5 | 1998 | 1171 | 0.070 |
Why?
|
| Leukemoid Reaction | 1 | 1985 | 15 | 0.070 |
Why?
|
| Cells, Cultured | 8 | 1999 | 19223 | 0.070 |
Why?
|
| Platelet Aggregation | 1 | 1989 | 800 | 0.070 |
Why?
|
| Alkaline Phosphatase | 1 | 1989 | 865 | 0.070 |
Why?
|
| Humans | 61 | 2017 | 742088 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2008 | 834 | 0.060 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 1985 | 80 | 0.060 |
Why?
|
| Adenine | 1 | 1990 | 936 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 3391 | 0.060 |
Why?
|
| Carcinoid Tumor | 1 | 1986 | 235 | 0.060 |
Why?
|
| Guided Tissue Regeneration | 1 | 2005 | 85 | 0.060 |
Why?
|
| Translocation, Genetic | 1 | 1990 | 1417 | 0.060 |
Why?
|
| Lung | 3 | 1999 | 9826 | 0.060 |
Why?
|
| Agranulocytosis | 1 | 1984 | 100 | 0.060 |
Why?
|
| Cricetulus | 4 | 1989 | 817 | 0.060 |
Why?
|
| Hydrogen Peroxide | 3 | 1999 | 730 | 0.060 |
Why?
|
| Zidovudine | 3 | 1996 | 620 | 0.060 |
Why?
|
| Heparin | 2 | 1982 | 1636 | 0.060 |
Why?
|
| Adenoma, Islet Cell | 1 | 1983 | 82 | 0.060 |
Why?
|
| Adenocarcinoma | 4 | 2001 | 6347 | 0.060 |
Why?
|
| Reticulocytes | 1 | 1984 | 290 | 0.060 |
Why?
|
| Neural Tube Defects | 1 | 1985 | 255 | 0.060 |
Why?
|
| Asbestos | 1 | 1985 | 251 | 0.060 |
Why?
|
| Mediastinal Neoplasms | 1 | 1986 | 421 | 0.060 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1983 | 82 | 0.050 |
Why?
|
| Crossing Over, Genetic | 1 | 1983 | 95 | 0.050 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1984 | 142 | 0.050 |
Why?
|
| Rhode Island | 4 | 1988 | 347 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 1990 | 2940 | 0.050 |
Why?
|
| Drug Evaluation | 6 | 1990 | 637 | 0.050 |
Why?
|
| Xanthine Oxidase | 3 | 1987 | 64 | 0.050 |
Why?
|
| Mass Screening | 2 | 1988 | 5238 | 0.050 |
Why?
|
| Cell Line | 7 | 1990 | 15994 | 0.050 |
Why?
|
| Neutrophils | 2 | 1992 | 3711 | 0.050 |
Why?
|
| Hepatitis B virus | 1 | 1985 | 513 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2017 | 4369 | 0.050 |
Why?
|
| Orbital Neoplasms | 1 | 1983 | 225 | 0.050 |
Why?
|
| Combined Modality Therapy | 8 | 2001 | 8621 | 0.050 |
Why?
|
| Ovary | 4 | 1987 | 981 | 0.050 |
Why?
|
| Diagnosis | 1 | 1981 | 154 | 0.050 |
Why?
|
| Thiazoles | 1 | 1987 | 1484 | 0.040 |
Why?
|
| Enterococcus faecalis | 1 | 1981 | 251 | 0.040 |
Why?
|
| Egtazic Acid | 2 | 1990 | 173 | 0.040 |
Why?
|
| Meningitis | 1 | 1981 | 216 | 0.040 |
Why?
|
| Lymphoma | 1 | 2008 | 1873 | 0.040 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1980 | 188 | 0.040 |
Why?
|
| Medical Audit | 1 | 1980 | 467 | 0.040 |
Why?
|
| Platelet Count | 1 | 1982 | 780 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2008 | 2066 | 0.040 |
Why?
|
| Toxoplasmosis | 1 | 1979 | 91 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 1992 | 3497 | 0.040 |
Why?
|
| Adult | 20 | 2008 | 213712 | 0.040 |
Why?
|
| Leucovorin | 3 | 1996 | 624 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2001 | 2876 | 0.040 |
Why?
|
| Female | 32 | 2008 | 379592 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 1992 | 2861 | 0.040 |
Why?
|
| Colonic Neoplasms | 3 | 1988 | 2542 | 0.040 |
Why?
|
| Aged | 23 | 2008 | 162944 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 1596 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1986 | 2231 | 0.040 |
Why?
|
| Hepatitis | 1 | 1979 | 227 | 0.040 |
Why?
|
| Oxidation-Reduction | 4 | 1987 | 2187 | 0.040 |
Why?
|
| Drug Synergism | 2 | 1993 | 1791 | 0.040 |
Why?
|
| Mannitol | 2 | 1990 | 181 | 0.040 |
Why?
|
| Leukocyte Count | 3 | 1992 | 1583 | 0.040 |
Why?
|
| Computers | 1 | 1979 | 611 | 0.040 |
Why?
|
| Male | 29 | 2008 | 349538 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 1985 | 1887 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 1984 | 1413 | 0.030 |
Why?
|
| Middle Aged | 23 | 2008 | 213127 | 0.030 |
Why?
|
| Adenosine Diphosphate | 2 | 1989 | 425 | 0.030 |
Why?
|
| Medical Staff, Hospital | 1 | 1980 | 603 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 1980 | 1179 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 1981 | 503 | 0.030 |
Why?
|
| Phenotype | 1 | 1993 | 16331 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1979 | 783 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1980 | 740 | 0.030 |
Why?
|
| Neoplasm Staging | 4 | 2001 | 11001 | 0.030 |
Why?
|
| Electromagnetic Fields | 1 | 1996 | 298 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 1985 | 3164 | 0.030 |
Why?
|
| Remission Induction | 4 | 1992 | 2384 | 0.030 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1993 | 110 | 0.030 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1992 | 87 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 1993 | 217 | 0.030 |
Why?
|
| Animals | 16 | 1996 | 168561 | 0.020 |
Why?
|
| Blood Platelets | 1 | 1982 | 2506 | 0.020 |
Why?
|
| Clinical Trials as Topic | 3 | 2005 | 7901 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2001 | 6891 | 0.020 |
Why?
|
| Leukocytosis | 1 | 1992 | 247 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1981 | 1884 | 0.020 |
Why?
|
| Cyclophosphamide | 2 | 1988 | 2236 | 0.020 |
Why?
|
| Mouth Neoplasms | 2 | 1986 | 601 | 0.020 |
Why?
|
| Photofluorography | 1 | 1989 | 4 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2001 | 4029 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 1992 | 625 | 0.020 |
Why?
|
| Cytochrome c Group | 1 | 1989 | 128 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2010 | 62966 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 1993 | 931 | 0.020 |
Why?
|
| Injections, Subcutaneous | 2 | 1982 | 664 | 0.020 |
Why?
|
| Ristocetin | 1 | 1989 | 26 | 0.020 |
Why?
|
| Piroxicam | 1 | 1988 | 19 | 0.020 |
Why?
|
| Lipoxygenase | 1 | 1988 | 74 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 1990 | 270 | 0.020 |
Why?
|
| Hemorrhage | 1 | 1981 | 3461 | 0.020 |
Why?
|
| Survival Rate | 2 | 2001 | 12773 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 1990 | 898 | 0.020 |
Why?
|
| Rectal Neoplasms | 2 | 1988 | 1195 | 0.020 |
Why?
|
| Methylthioinosine | 1 | 1988 | 4 | 0.020 |
Why?
|
| Vindesine | 1 | 1988 | 12 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 1999 | 3081 | 0.020 |
Why?
|
| Karyotyping | 1 | 1990 | 1243 | 0.020 |
Why?
|
| Indomethacin | 1 | 1988 | 331 | 0.020 |
Why?
|
| Nicotine | 1 | 1993 | 677 | 0.020 |
Why?
|
| Students, Medical | 1 | 1981 | 1858 | 0.020 |
Why?
|
| Thiazolidines | 1 | 1987 | 74 | 0.020 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 1987 | 65 | 0.020 |
Why?
|
| Aged, 80 and over | 6 | 2008 | 57683 | 0.020 |
Why?
|
| Inosine | 1 | 1988 | 133 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 1986 | 54 | 0.020 |
Why?
|
| Time Factors | 3 | 2001 | 40054 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 1987 | 434 | 0.020 |
Why?
|
| Pneumonia | 1 | 1978 | 2117 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2001 | 4229 | 0.020 |
Why?
|
| Hypoxanthines | 1 | 1985 | 35 | 0.020 |
Why?
|
| Hypoxanthine | 1 | 1985 | 28 | 0.020 |
Why?
|
| Selenious Acid | 1 | 1985 | 6 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2001 | 39004 | 0.020 |
Why?
|
| Benzoic Acid | 1 | 1985 | 15 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1993 | 1548 | 0.020 |
Why?
|
| NAD | 1 | 1989 | 594 | 0.020 |
Why?
|
| Infusions, Intravenous | 4 | 1992 | 2271 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 1983 | 5249 | 0.020 |
Why?
|
| Fetus | 1 | 1993 | 1879 | 0.020 |
Why?
|
| Liver Neoplasms | 2 | 1998 | 4249 | 0.020 |
Why?
|
| Hepatitis B Core Antigens | 1 | 1985 | 92 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 1992 | 10943 | 0.020 |
Why?
|
| Methionine | 1 | 1987 | 590 | 0.020 |
Why?
|
| Procarbazine | 1 | 1984 | 181 | 0.020 |
Why?
|
| Mechlorethamine | 1 | 1984 | 136 | 0.020 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1985 | 305 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 1984 | 163 | 0.010 |
Why?
|
| Hepatitis B Vaccines | 1 | 1985 | 194 | 0.010 |
Why?
|
| Acetylcysteine | 1 | 1985 | 272 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1986 | 434 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1990 | 2633 | 0.010 |
Why?
|
| Benzoates | 1 | 1985 | 217 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 1993 | 12958 | 0.010 |
Why?
|
| Selenium | 1 | 1985 | 402 | 0.010 |
Why?
|
| Lymphocytosis | 1 | 1983 | 119 | 0.010 |
Why?
|
| Kinetics | 1 | 1990 | 6474 | 0.010 |
Why?
|
| Carotenoids | 1 | 1985 | 624 | 0.010 |
Why?
|
| Vincristine | 1 | 1984 | 1036 | 0.010 |
Why?
|
| Diplopia | 1 | 1983 | 199 | 0.010 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1981 | 43 | 0.010 |
Why?
|
| Health Education | 1 | 1988 | 1053 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 1982 | 263 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1985 | 1458 | 0.010 |
Why?
|
| Mice, Inbred C3H | 2 | 1996 | 964 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 1978 | 5169 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1980 | 5774 | 0.010 |
Why?
|
| Hepatitis B | 1 | 1985 | 695 | 0.010 |
Why?
|
| Prednisone | 1 | 1984 | 1567 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1990 | 5975 | 0.010 |
Why?
|
| Syndrome | 1 | 1985 | 3248 | 0.010 |
Why?
|
| Breast Neoplasms | 3 | 1998 | 20774 | 0.010 |
Why?
|
| Leukocytes | 1 | 1985 | 2039 | 0.010 |
Why?
|
| Granuloma | 1 | 1979 | 315 | 0.010 |
Why?
|
| Spleen | 1 | 1983 | 2359 | 0.010 |
Why?
|
| Prognosis | 3 | 1993 | 29010 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1989 | 3067 | 0.010 |
Why?
|
| Monocytes | 1 | 1985 | 2593 | 0.010 |
Why?
|
| Pineal Gland | 1 | 1996 | 165 | 0.010 |
Why?
|
| Aortic Aneurysm | 1 | 1980 | 643 | 0.010 |
Why?
|
| Adolescent | 2 | 1993 | 85649 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1996 | 876 | 0.010 |
Why?
|
| Vaccination | 1 | 1985 | 3256 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2001 | 77098 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1984 | 4554 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1992 | 25575 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1996 | 1263 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 1983 | 2643 | 0.010 |
Why?
|
| Pregnancy | 1 | 1992 | 29087 | 0.010 |
Why?
|
| Melatonin | 1 | 1996 | 720 | 0.010 |
Why?
|
| Leukopenia | 1 | 1990 | 208 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 2191 | 0.010 |
Why?
|
| Age Factors | 3 | 1990 | 18355 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1996 | 2964 | 0.000 |
Why?
|
| Drug Administration Schedule | 1 | 1996 | 4929 | 0.000 |
Why?
|
| DNA, Neoplasm | 1 | 1992 | 1758 | 0.000 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 1986 | 62 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1996 | 6382 | 0.000 |
Why?
|
| Mesocricetus | 1 | 1986 | 251 | 0.000 |
Why?
|
| Ovarian Neoplasms | 1 | 1983 | 4823 | 0.000 |
Why?
|
| Mastectomy, Segmental | 1 | 1989 | 955 | 0.000 |
Why?
|
| Liver | 1 | 1979 | 7470 | 0.000 |
Why?
|
| Hyperplasia | 1 | 1986 | 1183 | 0.000 |
Why?
|
| Inflammation | 1 | 1983 | 10578 | 0.000 |
Why?
|
| Hematologic Diseases | 1 | 1987 | 498 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 7721 | 0.000 |
Why?
|
| Environmental Exposure | 1 | 1996 | 4231 | 0.000 |
Why?
|
| Periodontal Diseases | 1 | 1984 | 449 | 0.000 |
Why?
|
| Mastectomy | 1 | 1989 | 1789 | 0.000 |
Why?
|
| Postoperative Care | 1 | 1986 | 1484 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1978 | 7153 | 0.000 |
Why?
|
| Patient Participation | 1 | 1989 | 1445 | 0.000 |
Why?
|
| Radiotherapy | 1 | 1986 | 1525 | 0.000 |
Why?
|
| Neoplasms, Experimental | 1 | 1984 | 1274 | 0.000 |
Why?
|
| Mice, Nude | 1 | 1985 | 3689 | 0.000 |
Why?
|
| Family | 1 | 1989 | 3144 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1988 | 6483 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1987 | 2145 | 0.000 |
Why?
|
| Mice | 2 | 1996 | 81045 | 0.000 |
Why?
|
| Rats | 1 | 1991 | 24265 | 0.000 |
Why?
|
| Cohort Studies | 1 | 1989 | 40450 | 0.000 |
Why?
|
Concepts
(290)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(4)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_